Home›Trial›NCT04716231
🔬NCT04716231Phase 3ACTIVE NOT RECRUITING

Atacicept in Subjects With IgA Nephropathy

Study Summary

A Phase 3 Study with Atacicept in Subjects With IgA Nephropathy (ORIGIN 3)

Conditions
IgA NephropathyBerger Disease
Interventions / Drugs
AtaciceptPlacebo to match Atacicept
View on ClinicalTrials.gov ↗
Sponsor
VERA
Vera Therapeutics
Nephrology
C56/100
Study Details
Enrollment376 participants
Primary Completion—
Lead SponsorVera Therapeutics, Inc.
Data Retrieved2026-04-11 04:30:54.036488+00:00
Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.